Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

PTEN is a phosphatase which metabolises PIP 3, the lipid product of PI 3-Kinase, directly
opposing the activation of the oncogenic PI3K/AKT/mTOR signalling network. Accordingly …

Breast cancer is the cancer with the highest prevalence in women and is the number‐one
cause of cancer mortality worldwide. Cell transduction is a fundamental process in the …

Abstract Background TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of
prostate cancer. To compare the genomic alteration landscapes of EO-PCA with" …

Background Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) occurs
frequently in prostate cancers. Preclinical evidence suggests that activation of PI3K/AKT …

Abstract Context Prostate cancer (PCa) is a clinically heterogeneous disease with marked
variability in patient outcomes. Molecular characterization has revealed striking mutational …